Literature DB >> 9049825

Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.

J A Toretsky1, Y Connell, L Neckers, N K Bhat.   

Abstract

Ewing's sarcoma family of tumors (EFT) contain reciprocal translocations, of which approximately 90% occur between the long arm of chromosomes 11 and 22,t(11;22)(q24;q12) resulting in the formation of chimeric proteins generated by a fusion of the EWS and FLI-1 genes. To determine if EWS-FLI-1 protein is responsible for the Ewing sarcoma phenotype we have used sequence-specific antisense oligodeoxynucleotides (ODN) to block its expression. We have evaluated a series of antisense ODN directed toward the breakpoint region in an effort to prevent translation of the fusion messenger RNA. ODN were first evaluated in a cell-free in vitro translation system. Exogenously added RNase H was found to be required for translation inhibition. ODN that showed complete inhibition of translation were electroporated into TC-32 cells, a EFT cell line. Fusion protein and EWS protein levels were evaluated by Western blot analysis. A 40-60% decrease in the fusion protein was observed in TC-32 cells with antisense ODN directed toward the breakpoint region. Cell viability was reduced with antisense sequences in TC-32 cells but not in a prostate cancer cell line. Since inhibition of t(11:22) gene product is correlated to effects on cell viability reduction of the fusion protein may thus offer insight into the biology of EFT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049825     DOI: 10.1023/a:1005716926800

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

Review 1.  Ribonuclease H-mediated inhibition of translation and reverse transcription by antisense oligodeoxynucleotides.

Authors:  C Boiziau; B Larrouy; S Moreau; C Cazenave; D Shire; J J Toulmé
Journal:  Biochem Soc Trans       Date:  1992-11       Impact factor: 5.407

2.  Characterization and uses of monoclonal antibody derived against DNA binding domain of the ets family of genes.

Authors:  N K Bhat; T S Papas
Journal:  Hybridoma       Date:  1992-06

3.  Selection of high-affinity RNA ligands to reverse transcriptase: inhibition of cDNA synthesis and RNase H activity.

Authors:  H Chen; L Gold
Journal:  Biochemistry       Date:  1994-07-26       Impact factor: 3.162

4.  Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors.

Authors:  J A Toretsky; L Neckers; L H Wexler
Journal:  J Natl Cancer Inst       Date:  1995-03-01       Impact factor: 13.506

5.  Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

Authors:  T Skorski; M Nieborowska-Skorska; N C Nicolaides; C Szczylik; P Iversen; R V Iozzo; G Zon; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

6.  Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation.

Authors:  B Plougastel; J Zucman; M Peter; G Thomas; O Delattre
Journal:  Genomics       Date:  1993-12       Impact factor: 5.736

7.  Antisense L/D-oligodeoxynucleotide chimeras: nuclease stability, base-pairing properties, and activity at directing ribonuclease H.

Authors:  M J Damha; P A Giannaris; P Marfey
Journal:  Biochemistry       Date:  1994-06-28       Impact factor: 3.162

8.  ERG gene is translocated in an Ewing's sarcoma cell line.

Authors:  T Dunn; L Praissman; N Hagag; M V Viola
Journal:  Cancer Genet Cytogenet       Date:  1994-08

9.  The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.

Authors:  W A May; S L Lessnick; B S Braun; M Klemsz; B C Lewis; L B Lunsford; R Hromas; C T Denny
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction.

Authors:  M Peter; H Magdelenat; J Michon; T Melot; O Oberlin; J M Zucker; G Thomas; O Delattre
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more
  29 in total

1.  Primitive neuroectodermal tumor of ovary in a young lady, confirmed with molecular and cytogenetic results--a rare case report with a diagnostic and therapeutic challenge.

Authors:  Vikas Ostwal; Bharat Rekhi; Vanita Noronha; Ranjan Basak; Sangeeta B Desai; Amita Maheshwari; Kumar Prabhash
Journal:  Pathol Oncol Res       Date:  2012-02-05       Impact factor: 3.201

Review 2.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

3.  Neural differentiation arrest in embryonal carcinoma cells with forced expression of EWS-FLI1.

Authors:  Yu Yang; Lanjing Zhang; Yanyu Wei; Hua Wang; Mariko Fukuma; Hao Xu; Wei Xiong; Jie Zheng
Journal:  J Neurooncol       Date:  2008-07-12       Impact factor: 4.130

Review 4.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

5.  Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.

Authors:  Vittorio Caropreso; Emad Darvishi; Thomas J Turbyville; Ranjala Ratnayake; Patrick J Grohar; James B McMahon; Girma M Woldemichael
Journal:  J Biol Chem       Date:  2016-03-09       Impact factor: 5.157

6.  Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.

Authors:  Maria E Gierisch; Franziska Pfistner; Laura A Lopez-Garcia; Lena Harder; Beat W Schäfer; Felix K Niggli
Journal:  J Biol Chem       Date:  2016-11-08       Impact factor: 5.157

Review 7.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma.

Authors:  Patrick P Lin; Yongxing Wang; Guillermina Lozano
Journal:  Sarcoma       Date:  2010-10-05

9.  Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.

Authors:  Yang Liu; Joseph M Eckenrode; Yinan Zhang; Jianjun Zhang; Reiya C Hayden; Annet Kyomuhangi; Larissa V Ponomareva; Zheng Cui; Jürgen Rohr; Oleg V Tsodikov; Steven G Van Lanen; Khaled A Shaaban; Markos Leggas; Jon S Thorson
Journal:  J Med Chem       Date:  2020-11-16       Impact factor: 7.446

Review 10.  Ewing's sarcoma: standard and experimental treatment options.

Authors:  Vivek Subbiah; Pete Anderson; Alexander J Lazar; Emily Burdett; Kevin Raymond; Joseph A Ludwig
Journal:  Curr Treat Options Oncol       Date:  2009-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.